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ABSTRACT
Background: Human milk is a complex fluid comprised of myriad
substances, with one of the most abundant substances being a group
of complex carbohydrates referred to as human milk oligosaccha-
rides (HMOs). There has been some evidence that HMO profiles
differ in populations, but few studies have rigorously explored this
variability.
Objectives: We tested the hypothesis that HMO profiles differ in
diverse populations of healthy women. Next, we examined relations
between HMO and maternal anthropometric and reproductive in-
dexes and indirectly examined whether differences were likely re-
lated to genetic or environmental variations.
Design: In this cross-sectional, observational study, milk was collected
from a total of 410 healthy, breastfeeding women in 11 international
cohorts and analyzed for HMOs by using high-performance liquid
chromatography.
Results: There was an effect of the cohort (P , 0.05) on concen-
trations of almost all HMOs. For instance, the mean 3-fucosyllac-
tose concentration was.4 times higher in milk collected in Sweden
than in milk collected in rural Gambia (mean 6 SEM: 473 6 55
compared with 103 6 16 nmol/mL, respectively; P , 0.05), and
disialyllacto-N-tetraose (DSLNT) concentrations ranged from
216 6 14 nmol/mL (in Sweden) to 870 6 68 nmol/mL (in rural
Gambia) (P , 0.05). Maternal age, time postpartum, weight, and
body mass index were all correlated with several HMOs, and multiple
differences in HMOs [e.g., lacto-N-neotetrose and DSLNT] were
shown between ethnically similar (and likely genetically similar) pop-
ulations who were living in different locations, which suggests that the
environment may play a role in regulating the synthesis of HMOs.
Conclusions: The results of this study support our hypothesis that
normal HMO concentrations and profiles vary geographically, even in
healthy women. Targeted genomic analyses are required to determine
whether these differences are due at least in part to genetic variation.
A careful examination of sociocultural, behavioral, and environmen-
tal factors is needed to determine their roles in this regard. This study
was registered at clinicaltrials.gov as NCT02670278. Am J
Clin Nutr 2017;105:1086–100.
Keywords: breastfeeding, carbohydrates, human milk, lactation,
oligosaccharides
INTRODUCTION
Human milk oligosaccharides (HMOs)23 are complex glycans
that are highly abundant in human milk (1). Mature human milk
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contains from 5 to 20 g HMOs/L, which often exceed concen-
trations of protein (2–7); concentrations are even higher in co-
lostrum (2, 8). In contrast, bovine milk contains lesser amounts
of oligosaccharides, and their structures differ greatly from those
in human milk (9–12). Decades of research have suggested that
HMOs may be important for nourishing health-promoting bac-
teria in the breastfed infant’s gastrointestinal tract (13–17), and
emerging research suggests that HMOs act as antiadhesives,
thereby reducing pathogen attachment and infectivity (18–22).
HMOs also appear to act as antimicrobials that prevent pathogen
proliferation (23) and as epithelial and immune cell modulators
that affect host responses (24–26). HMOs may even be involved
in brain development (27). As such, an understanding of HMO
origins and functions, many of which are structure specific (28),
as well as variations in intake by infants may lend key insights
into the optimization of infant health and wellbeing during this
critical phase of the life cycle.
Although there are substantial variations in HMO concen-
trations and profiles in women (29), very little is known about
the basis of this variability aside from the activity of galactoside
2-a-L-fucosyltransferase 2 (FUT2) and galactoside 3/4-L-fucosyl-
transferase (FUT3) genes, which influence the presence or
absence of a1-2-fucosylated and a1-3/4-fucosylated HMOs,
respectively, as well as many other HMO structures (30, 31).
Perhaps the most relevant study to date in which the interpopu-
lation variation in HMO profiles was investigated was conducted
by Erney et al. (32), who compared neutral oligosaccharides in
milk that were collected from 435 women who were living in 10
countries. Although the authors recognized that, in some cases,
small sample sizes within a country made comparisons and gen-
eralizations difficult, several findings were of significance. For
instance, 2#-fucosyllactose was quantifiable in every milk sample
that was collected in Mexico (n = 156) and Sweden (n = 7), but in
only 46% of samples that were collected in the Philippines
(n = 22). Sweden presented a particularly interesting picture
with all samples containing 8 of 9 HMOs studied; none of the
samples contained 3-fucosyllactose.
The primary objective of this study was to expand on the work
of Erney et al. (32) to reexamine, with the use of more-advanced
methods and rigorous sampling approaches, the hypothesis that
HMO concentrations and profiles differ in diverse populations.
As our secondary objective, we explored relations between selected
maternal variables andHMO concentrations; in a subset of samples,
we also indirectly examined whether differences in HMOs were
more likely related to genetic or environmental factors.
METHODS
Experimental design, subjects, and ethics approvals
This investigation took place between May 2014 and April
2016 and was carried out as a cross-sectional, epidemiologic
cohort study that involved multiple international sites. To be eli-
gible for participation, women had to be breastfeeding or pumping
$5 times/d (to ensure adequate milk production), have self-
reported having healthy and nursing healthy infants, be $18 y
of age, and be between 2 wk and 5 mo postpartum. Women did
not need to be exclusively breastfeeding. Exclusion criteria
included a current indication of a breast infection or breast pain
that the woman did not consider normal for lactation, the maternal
use of antibiotics in the previous 30 d, or the nursing of a child
with signs or symptoms of an acute illness in the previous 7 d or
having taken antibiotics in the previous 30 d.
Our sample included 2 European (Spanish and Swedish), 1
South American (Peruvian), 2 North American, and 6 sub-
Saharan African (rural and urban Ethiopian, rural and urban
Gambian, Ghanaian, and Kenyan) populations and cohorts.
Spanish subjects were recruited in Madrid, Zaragoza, Huesca,
and Vizcaya with no additional requirements in terms of eth-
nicity. Swedish subjects were recruited in or near Helsingborg
and had self-reported as Nordic (both parents and all grand-
parents were self-described as having only Swedish, Finnish,
Danish, Icelandic, or Norwegian heritage). Peruvian subjects
resided in a peri-urban area of Lima. North American subjects
were recruited in Southeastern Washington and Northwestern
Idaho [United States–Washington (USW)] and Southern California
[United States–California (Hispanic) (USC)]; the former group
was of unspecified ethnicity, and the latter group was self-
identified as Hispanic. Both rural and urban Ethiopian subjects
were self-identified as Sidama and were assumed to be genetically
similar. Rural Ethiopian participants resided in the highlands
of the Southern Nations, Nationalities, and Peoples’ Region,
whereas urban participants resided in Hawassa, which is also in
the Southern Nations, Nationalities, and Peoples’ Region. Rural
and urban Gambian subjects had self-identified as Mandinka and
were assumed to be genetically similar. Urban Gambian partici-
pants resided in the Bakau region, whereas the rural cohort
stemmed from the West Kiang region. Ghanaian subjects were
Krobo or Dangme and lived in southeastern Ghana. Kenyan
subjects were recruited from the multiethnic city of Nakuru. Our
goal was to obtain data and human milk samples from 40 women
in each cohort, which was a number that was primarily chosen to
fit within the available resources and time.
On enrollment, each woman completed several questionnaires
including one questionnaire that ensured eligibility and another
questionnaire that was related to general maternal and infant
health and anthropometric measures. Ethics approvals were
obtained for all procedures from each participating institution and
with overarching approval from the Washington State University
Institutional Review Board (13264). After being translated from
English (when needed), informed, verbal, or written consent
(depending on the locale and the subject’s literacy level) was
acquired from each participating woman.
Milk collection and preservation
With the use of gloved hands, research personnel or the mother
(depending on cultural acceptability) cleaned the study breast
(chosen by the subject) twice with the use of prepackaged castile
soap towelettes (Professional Disposables International Inc.) and
with a newly opened package each time. When deemed appro-
priate, this step was preceded by a general cleansing with water
(and soap if needed) to remove noticeable soil. In the cohorts in
Peru, Sweden, USC, and USW, #200-mL (typically 40–60-mL)
milk samples were collected into a single-use, sterile, poly-
propylene milk-collection container with a polybutylene tere-
phthalate cap (Medela Inc.) with the use of an electric breast
pump. In Spain, milk samples were collected via manual ex-
pression (with the use of a gloved hand) into single-use, sterile,
polypropylene milk-collection containers with polybutylene
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terephthalate caps (Medela Inc.). At the remaining sites, milk
was manually expressed (with the use of a gloved hand) into
sterile, polypropylene specimen containers with polyethylene
caps (VWR International LLC.). When necessary to collect
the desired volume or because the mother requested to switch
breasts, milk was expressed from both breasts; when this oc-
curred, the previously detailed methods were repeated with the
other breast. To help control for known and unknown biases that
might have been introduced through the use of different mate-
rials, all milk-collection supplies (e.g., gloves, wipes, and col-
lection containers) were standardized and provided to study
personnel at each site.
In all sites except rural Ethiopia (ETR) and Peru, milk was
immediately placed in ice or in a cold box (48C) where it re-
mained until it was partitioned, within 1 h, into aliquots. Milk
was frozen (2208C), shipped on dry ice (if necessary;278.58C),
and again frozen (2208C) until it was analyzed. In Peru, milk
was immediately partitioned into aliquots and frozen (2208C),
shipped on dry ice, and again frozen (2208C) until it was an-
alyzed. Because the ETR site did not have consistent access to
electricity, milk that was collected in this cohort was preserved
with a milk-preservation solution (one-to-one ratio) that was
contained in a Milk DNA Preservation and Isolation Kit (Norgen
Biotek Corp.); this preserved milk was stored at an ambient
temperature for#1 wk after which it was transferred to a freezer
(2208C), shipped on dry ice, and again frozen (2208C) until it
was analyzed. Unpublished data from our research group con-
firmed that the use of this preservation method did not influence
the HMO analysis (L Bode, MK McGuire, June 2016).
Oligosaccharide analysis
HPLC was used to characterize HMO in breast milk as pre-
viously described (33). Briefly, human milk (20 mL) was spiked
with raffinose (a non-HMO carbohydrate) as an internal standard
to allow for absolute quantification. Oligosaccharides were ex-
tracted with the use of high-throughput solid-phase extraction
over C18 and carbograph microcolumns (Thermo Scientific
HyperSep) and fluorescently labeled with 2-aminobenzamide.
Labeled oligosaccharides were analyzed with the use of HPLC
on an amide-80 column with an ammonium formate–acetonitrile
buffer system at a concentration of 50-mmol/L. Separation was
performed at 258C and was monitored with the use of a fluo-
rescence detector at a 360-nm excitation and 425-nm emission.
The peak annotation was based on standard retention times and a
mass spectrometric analysis with the use of a duo ion-trap mass
spectrometer (Thermo LCQ) that was equipped with a nano-
electrospray ionization source. Absolute concentrations were
calculated on the basis of standard response curves for each of
the annotated HMOs. The following 19 HMOs were identified
and quantified: 2#-fucosyllactose, 3-fucosyllactose, 3#-sialyllactose,
6#-sialyllactose, difucosyllactose, difucosyllacto-N-hexaose, difu-
cosyllacto-N-tetrose (DFLNT), disialyllacto-N-hexaose (DSLNH),
disialyllacto-N-tetraose (DSLNT), fucodisialyllacto-N-hexaose
(FDSLNH), fucosyllacto-N-hexaose (FLNH), lacto-N-fucopentaose
(LNFP) I, LNFP II, LNFP III, lacto-N-hexaose, lacto-N-neotetraose
(LNnT), lacto-N-tetrose (LNT), sialyl-lacto-N-tetraose b (LSTb), and
sialyl-lacto-N-tetraose c (LSTc). HMOs were also grouped accord-
ing to common structural elements. Secretor milk was defined as
having a 2#-fucosyllactose concentration that was greater than a
natural, very low break in the data. The total concentration of
HMOs was calculated as the sum of the annotated oligosac-
charides. The proportion of each HMO that made up the total
HMO concentration was also calculated. HMO concentrations
were analyzed with the use of both a molar-based unit of
measure (nanomoles per milliliter) and a weight-based unit
of measure (micrograms per milliliter). However, in the interest
of space and coherence, only the molar data are presented and
discussed in this article. Data that were analyzed on a weight
basis (micrograms per milliliter) are shown in Supplemental
Tables 1–9.
Statistical analysis
All exploratory and descriptive statistical analyses were per-
formed with the use of R software (version 3.3.2; R Foundation
for Statistical Computing) (34). To correct for nonnormal (right-
skewness) distributions, HMO quantities were log transformed
before analyses. The effect of the cohort on total, individual, and
grouped HMO concentrations was tested via 1-factor ANOVA
procedures with the use of the AOVoption in the stats package in
R software. Multiple comparisons were carried out with the use
of Bonferroni adjustment [LSD.test in the agricolae package
(35)] to assess differences in populations. Differences in pro-
portions of each cohort that were characterized as being secretors
were tested with the use of a chi-square post hoc procedure in the
NCStats package (36) with Benjamini and Hochberg false-
discovery-rate corrections (37). a-Diversity metrics including
richness, the Shannon diversity index, the inverse Simpson index,
Shannon evenness, Simpson evenness, and Pielou evenness were
computed (38). The AOV procedure was also used to examine the
effect of the cohort on richness, evenness, and diversity indexes
and to examine the effect of the cohort on selected metadata
[maternal age, parity, time postpartum, and BMI (in kg/m2)].
To visualize and characterize associations between individual
HMO or HMO profiles and selected metadata, heat maps of
Spearman-rank correlation coefficients were constructed with the
use of the corrplot package (39). To help control for the many
correlations in which we were interested while also wanting to
fully explore the many relations that might have been of interest
in this exploratory component of our data analysis, associations
were deemed significant with the assumption of a = 0.01.
Multivariate analyses to explore patterns and similarities in
complex HMO profiles were followed and included nonmetric
multidimensional scaling analyses with the use of a Bray-Curtis
dissimilarity matrix [metaMDS procedure in the vegan package
(38) and ggplot2 package (40) and a principle components
analysis princomp procedure in the stats base package of R
software]. Within these analyses, potential groupings of HMO
profiles by cohort, continent and ethnicity, BMI, time postpartum,
parity, and maternal age were examined. In this evaluation,
continuous variables were categorized as follows: BMI (,18.5,
18.5–24.9, and $25); time postpartum (quartiles: 20–46, 47–63,
64–78, and 79–161 d); parity (1, 2, and $3 children); and ma-
ternal age (quartiles: 18–22, 23–27, 28–32, and 33–46 y).
Nonnegative matrix factorization (NMF) was also used to dis-
cern potential patterns in the HMO profile data (41). In this set
of analyses, data were processed with the use of the Brunet
method (42), and 6 basis components were retained on the basis
of the rank estimate that was determined from the same package.
1088 McGUIRE ET AL.
Heat maps of the NMF feature scores were created with the
heatmap.2 procedure in the gplots package (43) to look for
patterns within the data structure (distinct from the correlation
maps and shown in Supplemental Figures 1 and 2).
RESULTS
Description of participating women
A total of 413 women were enrolled; 41, 40, 40, 40, 42, 42, 43,
41, 24, 41, and 19 women were from ETR, urban Ethiopia (ETU),
rural Gambia (GBR), urban Gambia (GBU), Ghana, Kenya, Peru,
Spain, Sweden, USW, and USC, respectively. Milk samples from
all of these women, except for 2 women in Ghana and 1 woman
in ETR, were successfully obtained and analyzed. Conse-
quently, data from a total of 410 women were included in our
analysis. Basic anthropometric and demographic information
of these participants is shown in Table 1. Several of these
classifications differed in the cohorts. For example, women in
ETU were younger than all other groups except for their
counterparts in ETR, GBR, Kenya, and Peru. Parity in women
in ETR and GBR was higher than that of women in ETU, Spain,
Sweden, and USW. Body weight also varied greatly in the
cohorts whereby women in Peru, Sweden, USC, USW, Spain,
Ghana, and GBU were relatively heavier and had higher BMI,
and women in ET and GBR were lighter and had lower BMI.
Note that groups in ETR than ETU as well as cohorts in GBR
than GBU were, for the most part, similar in terms of these
variables although parity was higher in women in ETR than in
ETU; there were no differences in these factors between the 2
US cohorts.
Effects of cohort on individual HMO concentrations and
HMO groupings
Mean values for individual and total HMO concentrations for
each cohort are provided in Table 2 (all women) and visually
depicted in Figure 1 (all women, secretors, and nonsecretors).
Relative abundances of each HMO in all women, secretors,
and nonsecretors in each cohort are shown in Figure 2. There
was an effect of the cohort on the total HMO concentration
and the concentrations of all the HMO types except for LNFP
I. For instance, DSLNT concentrations ranged from a low of
216 6 14 nmol/mL in Sweden to a high of 870 6 68 nmol/mL
in GBR (P , 0.05). LNFP III was significantly higher in milk
that was produced by Swedish women than by all other co-
horts (P , 0.05) except for women in the USC; and LSTb was
lower (P , 0.05) in milk that was produced by women in
Peru and the USC than by all other cohorts. In addition, al-
though they did not reach significance with the use of Bon-
ferroni correction for multiple comparisons, 2#-fucosyllactose
concentrations were 4–5 times higher in samples that were
collected in the USC (7043 6 858 nmol/L) and Peru (6528 6
435 nmol/L) than in those that were collected in Ghana (1428 6
207 nmol/mL).
Several differences were also shown between rural and urban
sites in Ethiopia and between rural and urban sites in The Gambia
despite the fact that, within each country, the populations studied
were expected to have been genetically related. For instance, in
The Gambia, the LNnT concentration of milk that was produced TA
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by the rural cohort was higher than that produced by the urban
cohort (1423 6 117 compared with 781 6 61 nmol/mL, re-
spectively; P , 0.05). The same difference was shown for
DSLNT (870 6 68 compared with 477 6 45 nmol/mL, re-
spectively; P , 0.05). Conversely, although they were similar
between rural and urban Gambian cohorts, concentrations of
6#-sialyllactose, LSTc, and FLNH were higher in milk that was
produced by mothers in ETU than by mothers in ETR.
There were also several differences between the 2 US pop-
ulations despite the fact that they were very similar in terms
of anthropometric and reproductive variables. For instance,
FDSLNH was higher in the USW group than in the USC group
(370 6 48 compared with 70 6 9 nmol/mL, respectively;
P , 0.05). Because both ethnicity and location, both of which
are likely related to environmental variables such as the diet,
were different between these groups; however, further work will
be required to tease apart potentially causative factors.
Other groupings of HMOs that are based on factors such as
HMO-bound sialic acid, chain type, and linkage type also
revealed differences in cohorts (Table 3). For instance, milk that
was produced by women in Sweden and the USC was the most
fucosylated and the least sialylated; milk from mother in ETR
was less sialylated than that of women in ETU; and milk pro-
duced by women in Peru was highly enriched with small HMOs
FIGURE 1 Mean 6 SEM absolute total and HMO isoform concentrations of all women combined (A), nonsecretors (B), and secretors (C). (A and B)
Bars without a common lowercase letter represent total HMO values that differed with the use of Bonferroni-correction procedures for multiple comparisons.
All statistical inferences were carried out on log-transformed data. Note that there was only one nonsecretor subject each in Peru and United States - CA. CA,
California; DFLac, difucosyllactose; DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetrose; DSLNH, disialyllacto-N-hexaose; DSLNT, dis-
ialyllacto-N-tetraose; FDSLNH, fucodisialyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human milk oligosaccharide; LNFP, lacto-N-fucopentaose;
LNH, lacto-N-hexaose; LNnT, lacto-N-neotetraose; LNT, lacto-N-tetrose; LSTb, sialyl-lacto-N-tetraose b; LSTc, sialyl-lacto-N-tetraose c; WA, Washington;
2#FL, 2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose; 6#SL, 6#-sialyllactose.
FIGURE 2 Mean 6 SEM relative abundance of HMO concentrations of all women combined (A), nonsecretors (B), and secretors (C) in each cohort.
Note that there was only one nonsecretor subject each in Peru and United States - CA. CA, California; DFLac, difucosyllactose; DFLNH, difucosyllacto-N-
hexaose; DFLNT, difucosyllacto-N-tetrose; DSLNH, disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fucodisialyllacto-N-hexaose;
FLNH, fucosyllacto-N-hexaose; HMO, human milk oligosaccharide; LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnT, lacto-N-neotetraose;
LNT, lacto-N-tetrose; LSTb, sialyl-lacto-N-tetraose b; LSTc, sialyl-lacto-N-tetraose c; WA, Washington; 2#FL, 2#-fucosyllactose; 3FL, 3-fucosyllactose;
3#SL, 3#-sialyllactose; 6#SL, 6#-sialyllactose.
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(defined as the sum of 2#-fucosyllactose, 3-fucosyllactose, 3#-
sialyllactose, and trisaccharides).
Effects of cohort on secretor status and of secretor status
on individual HMO concentrations
The proportion of women who were categorized as being se-
cretors (defined as having a 2#-fucosyllactose concentration that was
greater than a natural, very low break in the data) was also sub-
stantially different in populations (Figure 3) and ranged from 65%
in populations in GBR and ETR to 98% in the cohort in Peru
(P , 0.01). The percentage of secretors in the cohort in Peru was
also higher than that in the cohorts in Ghana and the USW (98%
compared with 68%, respectively; P , 0.01) but was similar to that
in the cohort in the USC (self-identified as Hispanic) (98% compared
with 95%; P = 1.00). As anticipated and as illustrated in Figures 1
and 2, absolute and relative HMO concentrations in secretors and
nonsecretors were substantially different (HMO concentrations by
secretor status are shown in Supplemental Tables 10–13).
Relations in selected maternal anthropometric,
demographic, or reproductive variables and individual
HMO concentrations
Variations in maternal age, time postpartum, BMI, and weight
were associatedwith several of the HMO types and groups (Figure
4). For instance, age was negatively correlated with concentra-
tions of LNnT, LSTc, and DSLNH (r = 20.14, 20.17, and
20.15, respectively) and was positively correlated with the con-
centration of FLNH (r = 0.15). Maternal weight and BMI were
positively correlated with 2#-fucosyllactose (r = 0.20 for both),
FLNH (r = 0.19 and 0.15, respectively), HMO-bound fucose
(r = 0.21 for both), and small HMOs (r = 0.21 and 0.23, re-
spectively); and maternal weight was positively correlated with
LNFP III (r = 0.20) and DFLNT (r = 0.14). Conversely, maternal
weight and BMI were inversely correlated with LNnT and DSLNT
(r = 20.16 and 20.21, respectively; and r = 20.20 and 20.24,
respectively). The time postpartum was inversely correlated
with several HMOs including 6#-sialyllactose, LNFP III, LSTc,
lacto-N-hexaose, DSLNT, and a2,6-linked oligosaccharides
(r =20.31,20.23,20.40,20.26,20.13, and20.36, respectively).
Relations between HMO concentrations
Several correlations also existed in the concentrations of different
HMOs and groups thereof. For instance, concentrations of 2#-
fucosyllactose, difucosyllactose, and LNFP I were all correlated
(r = 0.23–0.54); this correlation was expected because their syn-
thesis in the mammary gland is dependent on FUT2 activity.
Similarly, concentrations of HMO-bound fucose and a1-2-fucosy-
lated HMOwere correlated (r = 0.82) as were 2#-fucosyllactose and
combined small HMOs (r = 0.98). There was also a positive as-
sociation between LNTand LNnT concentrations (r = 0.75). LNFP I
and LNFP II were negatively correlated (r = 20.46); and 2#-
fucosyllactose was negatively correlated with LNFP II (r =20.52).
Other associations of interest were that both LNT and LNnT were
positively correlated with DSLNT (r = 0.60 and 0.62, respectively),
and LSTb was positively correlated with DSLNT (r = 0.55).
Effect of cohort on HMO diversity
Diversity metrics also differed in cohorts, and mean values are
provided in Table 4. In general, HMO diversity and evenness were
lowest in milk that was produced by women in Peru and the USC and
FIGURE 3 Percentages of women in each cohort categorized as secretors. Cohorts that do not share a common lowercase letter differ (P, 0.05) in terms
of their percentages of women who were secretors with the use of a chi-square test with Benjamini and Hochberg false-discovery-rate corrections. ETR, rural
Ethiopia; ETU, urban Ethiopia; GBR, rural Gambia; GBU, urban Gambia; GN, Ghana; KE, Kenya; PE, Peru; SP, Spain; SW, Sweden; USC, United States–
California (Hispanic); USW, United States–Washington.
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were highest in milk that was produced by women in Ghana. There
were no differences in HMO diversity between rural and urban co-
horts in either ET or GB cohorts or between US cohorts (see Sup-
plemental Tables 14 and 15 for diversity metrics by secretor status).
Effects of cohort and other factors on complex milk
oligosaccharide profiles
A visual and numerical evaluation of nonmetric dimensional
scaling and principle components analyses and plots (color coded
by cohort, continent and ethnicity, BMI, time postpartum, parity,
and maternal age) provided no discernible evidence that these
factors accounted for an appreciable variability in the overall
HMO profiles (MK McGuire, SL Brooker, WJ Price, B Shafii,
unpublished results, June 2016). To account for the multivariate
nature of the data, the NMF method was considered (43). The
basic purpose of the NMF analysis was to decompose the data
matrix into metacomponents and to determine their potential
probabilities of contribution to the underlying variability struc-
ture. For example, as shown in Table 5, overall scores were used
FIGURE 4 Spearman rank correlations between selected maternal anthropometric, demographic, and reproductive variables and HMO types and
groupings. Sizes of dots and colors indicate directionality (blue denotes positive; red denotes negative) and the strength of the association. Total HMO-
bound sialic acid; total HMO-bound fucose; small HMO; type 1; type 2; a-1,2; a-1,3; and a-2,6 were calculated as: the sum of all sialic acid moieties bound to
each HMO; all fucose moieties bound to each HMO; 2#FL + 3FL + 3#SL + 6#SL; LNT + LNFPI + LNFPII + LSTb + DSLNT; LNnT + LNFPIII + LSTc;
LNFP I + 2#FL; LNFP III + 3FL; and LSTb + LSTc + 6#SL, respectively. DFLac, difucosyllactose; DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-
tetrose; DSLNH, disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fucodisialyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human
milk oligosaccharide; LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnT, lacto-N-neotetraose; LNT, lacto-N-tetrose; LST, sialyl-lacto-N-tetraose; 2#FL,
2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose; 6#SL, 6#-sialyllactose.
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to break down the probability of each HMO that contributed to
the observed pattern in the data with higher numbers having a
higher probability of contribution (i.e., 2#-fucosyllactose con-
tributed the most to the overall observed variability). Further
separation of the analysis, by dividing the data into subgroups
(such as population or BMI range), allowed for analysis of how
these same components contributed to specified subsets of the
data. Several detectable patterns were apparent when the NMF
was used to analyze subgroups of the data. The extraction
of HMO components with the highest feature scores led to 6
compounds (2#-fucosyllactose, LNFP I, LNFP II, 6#-sialy-
llactose, DFLNT, and FDSLNH); NMF scores for these HMOs
(Supplemental Figure 1, Table 5) suggested that they contributed
differently to the overall structure of HMO profiles across
populations. For instance, 2#-fucosyllactose appeared to be highly
influential to the variability of HMO profiles in the groups in
Ghana, GBU, GBR, ETU, and ETR but was less important in most
other cohorts. DFLNT appeared to have a similar pattern, but it
was also important in Kenya. Another example was 6#-sialy-
llactose, which contributed substantially to HMO profiles in the
ETR, USW, USC, and Peru cohorts but in the other cohorts.
Contributions to HMO-profile variability also seemed to differ by
maternal BMI, parity, and time postpartum (Tables 6–8) (see
Supplemental Figures 2 and 3 for related basis maps). For
example, 2#-fucosyllactose was relatively more important in
healthy-weight and overweight women than in underweight
women, whereas difucosyllacto-N-hexaose was more important to
the data structure in underweight women. Difucosyllactose ap-
peared to decrease in relative contribution as BMI increased;
conversely, 6#-sialyllactose, FDSLNH, and DSLNH appeared to
increase in contribution as BMI increased. LNFP III was more
important to the overall data structure for primiparous women
than for multiparous women, and DSLNH has the greatest con-
tribution in milk that was collected between 20 and 46 d post-
partum. FLNH and DFLHN both contributed to lower amounts of
the data structure as women got older (Table 9) (see Supple-
mental Figure 2 for related basis maps).
DISCUSSION
Results from this study support our a priori hypothesis that
concentrations of individual oligosaccharides and groupings
thereof vary geographically in milk that is produced by healthy
women. Indeed, absolute concentrations of all HMOs except for
LNFP I varied in the studied cohorts. Because we took great care
to collect and analyze the samples in a similar manner, we
conclude that these differences are not a result of methodologic
variation. In some cases (e.g., LNnT in GBR compared with
GBU), differences occurred despite similar genetic backgrounds,
thereby suggesting that environmental factors may be important.
In other cases (e.g., 2#-fucosyllactose in the USC compared with
USW), differences occurred across populations despite similar
anthropometric and reproductive backgrounds, thereby sug-
gesting that genetics, epigenetics, or other undocumented factors
(e.g., micronutrient intake) also likely play important roles.
An understanding of the genesis and implications of HMO
variation is important because increasing literature has suggested
that individual HMOs might have particular structure-specific
effects on infant health and risk of disease. For example,
Mexican infants who received milk with low concentrations ofTA
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2#-fucosyllactose (nonsecretor milk) had higher diarrhea in-
cidence (44) than of those who consumed appreciably higher
amounts of 2#-fucosyllactose. Higher concentrations of FUT2-
dependent HMOs such as 2#-fucosyllactose were also correlated
with lower risk of allergy at 2 and 5 y of age in infants with high
hereditary allergy risk (45), and HMOs including 2#-fuco-
syllactose attenuated food allergy symptoms in a mouse model
(46). Data from our current study revealed significant variations
in secretor status and 2#-fucosyllactose concentrations across
global locations. Most strikingly, and similar to the reported
high percentage of secretors in Mexico (32), we also showed
very high percentages of secretors in women in PE and the USC
who self-identified as Hispanic. We hypothesize that this dif-
ference has been driven by evolutionary pressures that have con-
ferred 2#-fucosyllactose–related health benefits in these populations,
at least in their historical locations and within long-term behavioral
and environmental constructs.
Other HMO isoforms are also likely related to health and disease
risk in particular situations. For instance, a lower total HMO
concentration and a higher proportion of 3#-sialyllactose were
correlated with higher HIV transmission in Zambian infants (33),
and HIV infection in lactating women was correlated with dif-
ferences in HMOs both in Zambia and South Africa (33, 47).
Moreover, HMO compositions have been associated with infant
mortality and morbidity in HIV-exposed uninfected infants in
Zambia (48). As such, increased consumption of these HMOs
might be particularly important in this high-risk condition. Al-
derete et al. (49) have also shown that concentrations of individual
HMOs in mother’s milk were associated with infant weight as
well as lean and fat body masses in a US cohort. Similarly,
Charbonneau et al. (50) reported that milk that was produced by
Malawian mothers who were nursing severely stunted infants had
lower HMO concentrations than in milk that was produced by
mothers who were breastfeeding healthy-weight infants. Together,
these studies suggest that the variation in HMO composition may
affect the recipient infant’s metabolic phenotype, which is likely
mediated through the gastrointestinal microbiome.
Research from the Bode laboratory (51) has also indicated that
consumption of higher amounts of DSLNT, which is a sialylated
HMO, may have been protective against the development of
necrotizing enterocolitis-like symptoms in a rodent model. In the
current study, we showed that maternal weight and BMI were
inversely correlated with DSLNT concentrations, which suggest
that maternal factors may partially contribute to HMO composi-
tion. The NMF analysis also suggested that there were somewhat
different patterns in maternal BMI categories. Clearly, whether
maternal adiposity is causally related to milk DSLNT (or any other
HMO) concentration or HMO profiles or, instead, is a proxy for
other maternal and environmental variables could not be ascer-
tained from the current study. In addition, we recognize that body
weight and BMI are not good indicators of adiposity during the
postpartum period (52) and that other more sophisticated methods
(e.g., dual-energy X-ray absorptiometry) will be needed to in-
vestigate this relation more thoroughly.
Note that, except for mothers in the USC, the mean concen-
tration of 3-fucosyllactose in milk that was produced by the
Swedish mothers in the current study was .2 times that of milk
that was produced by women in all other cohorts. This result is
in contrast with the previous work of Erney et al. (32) who
detected no 3-fucosyllactose in the milk of Swedish mothers. In
TABLE 5
Overall and population-specific NMF scores for each HMO1
HMO
Ethiopia Gambia
Ghana
(n = 40)
Kenya
(n = 42)
Peru
(n = 43)
Spain
(n = 41)
Sweden
(n = 24)
United States
Overall
Rural
(n = 40)
Urban
(n = 40)
Rural
(n = 40)
Urban
(n = 40)
Washington
(n = 41)
California
(n = 19)
2#FL 0.43 0.30 0.39 0.41 0.43 0.45 0.98 0.63 0.68 0.60 0.62 1.00
3FL 0.26 0.13 0.19 0.42 0.42 0.44 0.46 0.58 0.36 0.55 0.60 0.50
LNnT 0.18 0.15 0.26 0.22 0.34 0.17 0.32 0.30 0.25 0.42 0.14 0.45
3#SL 0.19 0.08 0.27 0.14 0.09 0.14 0.17 0.33 0.20 0.07 0.26 0.19
DFLac 0.49 0.30 0.32 0.67 0.29 0.31 0.54 0.69 0.56 0.23 0.47 0.51
6#SL 0.45 0.49 0.36 0.18 0.46 0.28 0.40 0.33 0.13 0.16 0.74 0.70
LNT 0.34 0.29 0.48 0.22 0.65 0.22 0.44 0.23 0.33 0.29 0.40 0.55
LNFP I 0.44 0.30 0.42 0.43 0.60 0.61 0.66 0.52 0.53 0.59 0.52 0.79
LNFP II 0.34 0.36 0.51 0.39 0.32 0.49 0.57 0.46 0.65 0.31 0.47 0.63
LNFP III 0.22 0.18 0.16 0.20 0.34 0.61 0.15 0.13 0.39 0.37 0.33 0.42
LSTb 0.28 0.19 0.39 0.22 0.35 0.24 0.22 0.27 0.18 0.25 0.14 0.33
LSTc 0.34 0.23 0.23 0.17 0.21 0.17 0.21 0.32 0.06 0.14 0.55 0.46
DFLNT 0.44 0.28 0.38 0.72 0.46 0.72 0.74 0.85 0.56 0.59 0.71 0.72
LNH 0.25 0.35 0.39 0.19 0.19 0.30 0.41 0.43 0.51 0.28 0.20 0.22
DSLNT 0.15 0.16 0.19 0.20 0.32 0.23 0.23 0.28 0.14 0.22 0.25 0.23
FLNH 0.15 0.13 0.19 0.16 0.50 0.06 0.47 0.42 0.25 0.29 0.29 0.31
DFLNH 0.43 0.32 0.34 0.61 0.23 0.43 0.34 0.41 0.21 0.44 0.41 0.37
FDSLNH 0.47 0.45 0.48 0.52 0.36 0.60 0.55 0.64 0.56 0.39 0.42 0.63
DSLNH 0.54 0.24 0.50 0.28 0.41 0.46 0.35 0.61 0.09 0.18 0.14 0.52
1NMF scores represent the probability of contribution to (and importance of) a specified HMO variable to the basis component. DFLac, difucosyllactose;
DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetrose; DSLNH, disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fucodi-
sialyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human milk oligosaccharide; LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnT,
lacto-N-neotetraose; LNT, lacto-N-tetrose; LSTb, sialyl-lacto-N-tetraose b; LSTc, sialyl-lacto-N-tetraose c; NMF, nonnegative matrix factorization; 2#FL,
2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose; 6#SL, 6#-sialyllactose.
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addition, although 3-fucosyllactose varied in the populations we
studied, it was not the most variable, as suggested by Erney et al.
(32). Instead, FLNH and LNFP III were 2- and 3-times more
variable than 3-fucosyllactose. It is possible that methodologic
differences between studies might explain this discrepancy.
Our data also revealed correlations between individual HMOs,
which suggest that there are common synthetic pathways. Some
of these correlations were anticipated; for instance, there were
positive correlations between 2#-fucosyllactose, difucosyllactose,
and LNFP I, which are HMOs that are all a1-2-fucosylated and
highly depend on FUT2 activity. Other associations, such as the
positive correlation between LNT and LNnT, were surprising. We
had anticipated that the terminal galactose is either attached in
b1-3-linkage to derive type 1 chains (e.g., LNT) or attached in
b1-4-linkage to derive type 2 chains (e.g., LNnT); however, this
would have yielded a negative correlation between LNT and
LNnT, which suggests that other factors determine and limit
chain elongation. Future studies that include genomic and tran-
scriptomic data sets will help delineate HMO biosynthetic path-
ways and unravel how the synthesis of different HMOs is
controlled. Forthcoming studies should be designed to determine
correlations between HMOs and other milk components including
the diverse communities of bacteria that are known to be in hu-
man milk (53–55).
One of our secondary objectives was to compare and contrast
HMO contents and profiles between ethnically similar (and likely
genetically similar) populations who were living in different
locations. In this regard, note that there were several differences
between milk that was produced by women in GBU and GBR
(both Mandinka) and between milk that was produced by women
in ETU and ETR (both Sidama). This finding suggests that there
may be some effect of a relatively recent migration on the com-
position of HMOs rather than all of the variation being related
strictly to genetic factors or simple-to-measure anthropometric
and demographic variables. However, note that, unlike in all other
cohorts for which milk was preserved by cold storage, milk col-
lected from women in ETR was first chemically preserved.
Although our unpublished data (MK McGuire, KA Lackey,
June 2016) suggest that the preservation method does not in-
fluence our ability to accurately characterize microbial commu-
nities in human milk, additional studies should be conducted to
verify this finding.
In conclusion, the current study presents foundational data on
what can be considered normal with regard to the HMO com-
position of milk that is produced by relatively healthy women in
different locations around the world. Future studies are needed to
determine how the variation in HMO composition is related to
maternal and infant health and to generate hypotheses on HMO
structure-function relations that can be tested in preclinical and
clinical studies. Our data also provide a solid, and relatively
unique, foundation on which to assess the deviation from a
normal milk composition when women are not healthy (e.g., with
diabetes, mastitis, or HIV). Future studies concerning this topic
TABLE 7
NMF scores describing parity for individual HMOs1
HMO
Parity, children, n
1 (n = 159) 2 (n = 111) $3 (n = 250)
2#FL 0.99 0.97 0.65
3FL 0.47 0.35 0.43
LNnT 0.29 0.43 0.38
3#SL 0.18 0.20 0.12
DFLac 0.51 0.31 0.42
6#SL 0.65 0.64 0.54
LNT 0.46 0.51 0.45
LNFP I 0.78 0.76 0.70
LNFP II 0.68 0.45 0.56
LNFP III 0.55 0.38 0.21
LSTb 0.29 0.29 0.26
LSTc 0.42 0.54 0.41
DFLNT 0.75 0.66 0.69
LNH 0.22 0.27 0.17
DSLNT 0.16 0.25 0.27
FLNH 0.37 0.27 0.28
DFLNH 0.30 0.30 0.35
FDSLNH 0.63 0.55 0.55
DSLNH 0.51 0.41 0.55
1NMF scores represent the probability of contribution to (and importance
of) a specified HMO variable to the basis component. DFLac, difucosyllactose;
DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetrose; DSLNH,
disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fucodisia-
lyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human milk oligo-
saccharide; LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnT,
lacto-N-neotetraose; LNT, lacto-N-tetrose; LSTb, sialyl-lacto-N-tetraose b;
LSTc, sialyl-lacto-N-tetraose c; NMF, nonnegative matrix factorization;
2#FL, 2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose;
6#SL, 6#-sialyllactose.
TABLE 6
NMF scores describing BMI for individual HMOs1
HMO
BMI, kg/m2
Underweight
(,18.5; n = 22)
Healthy weight
(18.5–24.9; n = 242)
Overweight
($25; n = 139)
2#FL 0.48 1.00 0.64
3FL 0.43 0.42 0.32
LNnT 0.16 0.54 0.35
3#SL 0.19 0.16 0.22
DFLac 0.54 0.45 0.32
6#SL 0.34 0.62 0.69
LNT 0.35 0.44 0.55
LNFP I 0.56 0.75 0.60
LNFP II 0.50 0.59 0.52
LNFP III 0.42 0.42 0.50
LSTb 0.07 0.30 0.30
LSTc 0.27 0.48 0.43
DFLNT 0.69 0.70 0.73
LNH 0.18 0.25 0.18
DSLNT 0.26 0.24 0.13
FLNH 0.51 0.26 0.54
DFLNH 0.58 0.45 0.25
FDSLNH 0.41 0.63 0.62
DSLNH 0.28 0.48 0.61
1NMF scores represent the probability of contribution to (and importance
of) a specified HMO variable to the basis component. DFLac, difucosyllactose;
DFLNH, difucosyllacto-N-hexaose; DFLNT, difucosyllacto-N-tetrose; DSLNH,
disialyllacto-N-hexaose; DSLNT, disialyllacto-N-tetraose; FDSLNH, fuco-
disialyllacto-N-hexaose; FLNH, fucosyllacto-N-hexaose; HMO, human milk
oligosaccharide; LNFP, lacto-N-fucopentaose; LNH, lacto-N-hexaose; LNnT,
lacto-N-neotetraose; LNT, lacto-N-tetrose; LSTb, sialyl-lacto-N-tetraose
b; LSTc, sialyl-lacto-N-tetraose c; NMF, nonnegative matrix factorization;
2#FL, 2#-fucosyllactose; 3FL, 3-fucosyllactose; 3#SL, 3#-sialyllactose; 6#SL,
6#-sialyllactose.
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should strive to include women from regions (e.g., Asia) that were
not included in the current study andwomenwho are not healthy or
are nursing unhealthy infants. The identification of the variation of
the normal HMO composition in healthy women is just the be-
ginning of a broader attempt to understand how sociocultural,
evolutionary, environmental, and genomic aspects affect human
milk composition and, subsequently, infant health. We posit that
there is likely no one-size-fits-all construct when it comes to
human milk composition and, thus, infant nutrition. Instead, we
hypothesize that human milk composition has likely evolved
differentially in such a way as to optimally nourish infants who
are born in various social, environmental, genetic, and behavioral
contexts. Future studies should be designed in such a way to
examine this possibility and to also test it experimentally.
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